Treatment
Endocrine therapy clinical trials
We’re tracking 114 recruiting studies that include Endocrine therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT06953882RecruitingPhase 2
Skipping chemo after surgery for ER+ HER2- breast cancer
This study tests whether some people with a certain type of breast cancer (ER-positive, HER2-negative) can safely skip chemotherapy. After surgery, they receive a targeted pill (ribociclib) plus hormone therapy instead. The goal is to see if this approach works just as well with fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT06837792RecruitingPhase 2
T-DXd vs hormone therapy for HER2-low advanced breast cancer
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
SeoulAges 19 years+ - NCT05759546RecruitingPhase 2
Test a PARP and CDK4/6 medicine plus hormone therapy
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06917313RecruitingPhase 2
Fezolinetant for hot flashes in women with breast cancer on hormone therapy
This trial tests a drug called fezolinetant to see if it reduces hot flashes in women with HR+ breast cancer who are on hormone therapy (like tamoxifen or aromatase inhibitors). You need to be postmenopausal and having at least 7 moderate to severe hot flashes a day.
New Haven, ConnecticutAges 18 years+ - NCT05878314Recruiting
Testing how hormones and tumor markers guide breast cancer treatment
This study looks at how planned hormone (endocrine) treatment, the menstrual cycle, and lab markers from the tumor may help doctors choose the best treatment for early-stage, hormone-receptor–positive, HER2-negative breast cancer. It may help personalize decisions, including what to do before surgery.
TübingenAges 18 years+ - NCT06656624RecruitingPhase 2
Ribociclib plus hormone therapy for advanced breast cancer
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
Nanjing, JiangsuAges 18–99 - NCT07646171Recruiting
Everolimus After Alpelisib for Advanced Breast Cancer
This trial tests a drug called everolimus in women with hormone receptor-positive metastatic breast cancer who have already tried alpelisib (a PI3K inhibitor) combined with hormone therapy. The goal is to see if this next treatment can help control cancer growth.
Tel AvivAges 21 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Birmingham, AlabamaAges 18–60 - NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+ - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04305834RecruitingPhase 2
Abemaciclib plus hormone pills for metastatic breast cancer in older adults
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
Duarte, CaliforniaAges 70 years+ - NCT04383275RecruitingPhase 2
De-escalation trial for early HER2+ breast cancer
This Phase 2 study tests whether people with early-stage HER2-positive breast cancer may be treated with less intensive therapy, without losing effectiveness. You may be considered if your tumor is small, lymph nodes are negative, and your hormone (ER/PR) status and HER2 test results match the study groups.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04483804Recruiting
Using computer image features to study breast cancer
This study looks at breast cancer images to see whether computer-extracted patterns (“radiomics”) can help improve understanding of the disease. You may be included if your breast cancer diagnosis is confirmed and your medical records are complete.
Hanzhou, ZhejiangAges 18–80 - NCT04703244Recruiting
Testing patient tumor samples to create research models in breast cancer
This study collects tumor-related samples from people with invasive breast cancer who are having surgery after treatment before surgery. Researchers use your samples to create lab models (called PDX and organoids) to help study breast cancer and find better future treatments.
Rochester, MinnesotaAges 18 years+ - NCT04886531RecruitingPhase 2
Pre-surgery neratinib plus hormone therapy with trastuzumab
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
Chicago, IllinoisAges 18 years+ - NCT04923542RecruitingPhase 1/Phase 2
Targeted drug plus focused brain radiation for breast cancer
This study tests whether abemaciclib (a targeted pill) given with focused radiation to brain tumors can control hormone receptor–positive, HER2-negative breast cancer in the brain. It’s designed to see if the combination helps shrink or slow the growth of brain metastases while keeping side effects manageable.
Tampa, FloridaAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+ - NCT05297617RecruitingPhase 2
Shorter hormone therapy for low-risk postmenopausal breast cancer
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
LimogesAges 51 years+ - NCT05305092Recruiting
Study of memory and thinking in early breast cancer
This study checks how breast cancer affects memory and thinking before other treatments start. It may help doctors better understand cognitive changes and who is most at risk.
Xi'an, ShaanxiAges Any age - NCT05362760RecruitingPhase 4
Abemaciclib plus hormone therapy, with digital side-effect tracking
This trial tests whether adding abemaciclib to standard hormone (endocrine) therapy can improve outcomes for certain types of advanced breast cancer. It also uses a phone app to help you and the team track side effects so problems can be caught early.
AalenAges 18 years+ - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05838716RecruitingPhase 3
Vitamin D During Hormone Therapy for Prostate Cancer
This trial studies whether taking vitamin D while you are on prostate hormone therapy (ADT) affects your health outcomes. It may help by keeping vitamin D levels in a safe range during treatment.
Newark, DelawareAges 50 years+ - NCT05860465RecruitingPhase 2/Phase 3
Tested blood cancer medicine with hormone therapy for breast cancer
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
Guangzhou, GuangdongAges 18–75 - NCT05887102Recruiting
Program to help women take hormone pills after breast cancer
This study tests a pharmacy-based program (called PACHA) designed to help women remember and stick with hormone (endocrine) treatment after breast cancer. It may help by improving support and follow-through during the first months after starting the pills.
Québec, QuebecAges 18 years+
Common questions
- Are there clinical trials studying Endocrine therapy?
- Yes. Clin2 currently lists 114 recruiting studies that include Endocrine therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Endocrine therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Endocrine therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Endocrine therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.